Evotec and Odyssey Therapeutics launch AI-driven R&D partnership to accelerate autoimmune and inflammatory disease drug discovery
Executive summary: Evotec and Odyssey Therapeutics entered an AI-enabled R&D collaboration focused on autoimmune and inflammatory diseases, combining Odyssey’s disease biology knowledge with Evotec’s AI-driven discovery platform and screening capabilities. The partnership aims to accelerate hit discovery for Odyssey’s preclinical programs, potentially shortening timelines and reducing costs in a therapeutically competitive and biologically complex disease area.
Who is involved: Evotec (Germany-based drug discovery and development company) and Odyssey Therapeutics (US-based biotech focused on immunology and oncology targets).
Likely next: Generation and validation of hit series from the collaboration, followed by lead optimization and potential progression toward preclinical candidates, with updates expected in future pipeline disclosures.
Evotec and Odyssey Therapeutics have formed a collaboration that integrates Odyssey’s deep expertise in disease biology with Evotec’s AI-powered discovery platform, high-throughput screening, and proprietary compound libraries. The partnership aims to advance Odyssey’s early-stage programs by generating validated hit series against key targets in autoimmune and inflammatory diseases. This reflects a growing trend of biotech firms leveraging AI-enabled contract research organizations to de-risk and accelerate preclinical development. The collaboration does not disclose financial terms, pipeline specifics, or timelines for clinical advancement.
Timeline
- — Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases (PR Newswire)
Analysis — what this means
Likely next events
- Evotec to deliver validated hit series against Odyssey’s targets within 12–18 months
Sectors affected
- AI-enabled drug discovery
- Contract research and development services
- Autoimmune disease therapeutics
- Inflammatory disease drug development
Regulatory implications
- No direct regulatory implications at this preclinical collaboration stage
- Future IND-enabling studies will need to comply with FDA/EMA guidance on AI/ML in drug discovery
- Data generated may support regulatory submissions if used in IND packages
Historical parallels
- Similar to Exscientia’s collaboration with Bayer in oncology (2021), using AI to accelerate small molecule discovery
- Analogous to Recursion Pharmaceuticals’ partnerships with Bayer and Roche (2020–2023) for AI-driven target and compound discovery
- Comparable to Insilico Medicine’s work with Fosun Pharma (2022) on AI-generated preclinical candidates for fibrosis
Sources
- Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases — PR Newswire
Related cases
- Health In Tech reports strong Q2 2026 revenue and pipeline growth, signaling expanding demand for AI-driven healthcare solutions
- Gallbladder Cancer Foundation launches AI-enabled online hub, signaling growing digital health investment in rare disease support
- Nordic Capital agrees to sell ArisGlobal to Dassault Systèmes after scaling it into an AI-enabled life sciences platform
- Nokia and NestAI team up to deliver AI-powered, resilient communications for defense operations in contested environments